Difference between revisions of "Small cell lung cancer"
Jump to navigation
Jump to search
m (added header) |
m (formatting of headers) |
||
| Line 5: | Line 5: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| − | + | =Limited stage= | |
| − | + | ==Cisplatin 60 mg/m2, Etoposide 120 mg/m2, RT== | |
| − | + | ===Regimen=== | |
*[[Cisplatin (Platinol)]] 60 mg/m2 IV day 1 | *[[Cisplatin (Platinol)]] 60 mg/m2 IV day 1 | ||
*[[Etoposide (Vepesid)]] 120 mg/m2 IV days 1-3 | *[[Etoposide (Vepesid)]] 120 mg/m2 IV days 1-3 | ||
| Line 14: | Line 14: | ||
'''21-day cycles x 4-6 cycles''' | '''21-day cycles x 4-6 cycles''' | ||
| − | + | ===References=== | |
# Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999 Jan 28;340(4):265-71. [http://www.nejm.org/doi/full/10.1056/NEJM199901283400403 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/9920950 PubMed] | # Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999 Jan 28;340(4):265-71. [http://www.nejm.org/doi/full/10.1056/NEJM199901283400403 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/9920950 PubMed] | ||
| − | + | ==Cisplatin 80 mg/m2, Etoposide 100 mg/m2, RT== | |
| − | + | ===Regimen=== | |
*[[Cisplatin (Platinol)]] 80 mg/m2 IV day 1 | *[[Cisplatin (Platinol)]] 80 mg/m2 IV day 1 | ||
*[[Etoposide (Vepesid)]] 100 mg/m2 IV days 1-3 | *[[Etoposide (Vepesid)]] 100 mg/m2 IV days 1-3 | ||
| Line 25: | Line 25: | ||
'''28-day cycles x 4-6 cycles''' | '''28-day cycles x 4-6 cycles''' | ||
| − | + | ===References=== | |
# Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, Nishiwaki Y, Watanabe K, Noda K, Tamura T, Fukuda H, Saijo N. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002 Jul 15;20(14):3054-60. [http://jco.ascopubs.org/content/20/14/3054.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/12118018 PubMed] | # Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, Nishiwaki Y, Watanabe K, Noda K, Tamura T, Fukuda H, Saijo N. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002 Jul 15;20(14):3054-60. [http://jco.ascopubs.org/content/20/14/3054.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/12118018 PubMed] | ||
# Saito H, Takada Y, Ichinose Y, Eguchi K, Kudoh S, Matsui K, Nakagawa K, Takada M, Negoro S, Tamura K, Ando M, Tada T, Fukuoka M; West Japan Thoracic Oncology Group 9902. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol. 2006 Nov 20;24(33):5247-52. [http://jco.ascopubs.org/content/24/33/5247.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/17114657 PubMed] | # Saito H, Takada Y, Ichinose Y, Eguchi K, Kudoh S, Matsui K, Nakagawa K, Takada M, Negoro S, Tamura K, Ando M, Tada T, Fukuoka M; West Japan Thoracic Oncology Group 9902. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol. 2006 Nov 20;24(33):5247-52. [http://jco.ascopubs.org/content/24/33/5247.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/17114657 PubMed] | ||
| − | + | ==Cisplatin, Etoposide, RT -> Cisplatin & Irinotecan== | |
| − | + | ===Regimen=== | |
*[[Cisplatin (Platinol)]] 80 mg/m2 IV day 1 | *[[Cisplatin (Platinol)]] 80 mg/m2 IV day 1 | ||
*[[Etoposide (Vepesid)]] 100 mg/m2 IV days 1-3 | *[[Etoposide (Vepesid)]] 100 mg/m2 IV days 1-3 | ||
| Line 42: | Line 42: | ||
'''28-day cycles x 3 cycles''' | '''28-day cycles x 3 cycles''' | ||
| − | + | ===References=== | |
# Saito H, Takada Y, Ichinose Y, Eguchi K, Kudoh S, Matsui K, Nakagawa K, Takada M, Negoro S, Tamura K, Ando M, Tada T, Fukuoka M; West Japan Thoracic Oncology Group 9902. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol. 2006 Nov 20;24(33):5247-52. [http://jco.ascopubs.org/content/24/33/5247.full link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17114657 PubMed] | # Saito H, Takada Y, Ichinose Y, Eguchi K, Kudoh S, Matsui K, Nakagawa K, Takada M, Negoro S, Tamura K, Ando M, Tada T, Fukuoka M; West Japan Thoracic Oncology Group 9902. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol. 2006 Nov 20;24(33):5247-52. [http://jco.ascopubs.org/content/24/33/5247.full link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17114657 PubMed] | ||
| − | + | ==Carboplatin, Etoposide, RT == | |
| − | + | ===Regimen=== | |
*[[Carboplatin (Paraplatin)]] AUC 5-6 IV over 1 hour on day 1 (administered first) | *[[Carboplatin (Paraplatin)]] AUC 5-6 IV over 1 hour on day 1 (administered first) | ||
*[[Etoposide (Vepesid)]] 100 mg/m2 IV over 2 hours on days 1-3 (administered second) | *[[Etoposide (Vepesid)]] 100 mg/m2 IV over 2 hours on days 1-3 (administered second) | ||
| Line 53: | Line 53: | ||
'''21-day cycles x up to 6 cycles''' | '''21-day cycles x up to 6 cycles''' | ||
| − | + | ===References=== | |
# Skarlos DV, Samantas E, Briassoulis E, Panoussaki E, Pavlidis N, Kalofonos HP, Kardamakis D, Tsiakopoulos E, Kosmidis P, Tsavdaridis D, Tzitzikas J, Tsekeris P, Kouvatseas G, Zamboglou N, Fountzilas G. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2001 Sep;12(9):1231-8. [http://annonc.oxfordjournals.org/content/12/9/1231.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11697833 PubMed] | # Skarlos DV, Samantas E, Briassoulis E, Panoussaki E, Pavlidis N, Kalofonos HP, Kardamakis D, Tsiakopoulos E, Kosmidis P, Tsavdaridis D, Tzitzikas J, Tsekeris P, Kouvatseas G, Zamboglou N, Fountzilas G. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2001 Sep;12(9):1231-8. [http://annonc.oxfordjournals.org/content/12/9/1231.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11697833 PubMed] | ||
| − | + | =Extensive stage= | |
| − | + | ==Cisplatin 75 mg/m2 & Etoposide 100 mg/m2== | |
| − | + | ===Regimen=== | |
*[[Cisplatin (Platinol)]] 75 mg/m2 IV day 1 | *[[Cisplatin (Platinol)]] 75 mg/m2 IV day 1 | ||
*[[Etoposide (Vepesid)]] 100 mg/m2 IV days 1-3 | *[[Etoposide (Vepesid)]] 100 mg/m2 IV days 1-3 | ||
| Line 64: | Line 64: | ||
'''21-day cycles x 4-6 cycles''' | '''21-day cycles x 4-6 cycles''' | ||
| − | + | ===References=== | |
# Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S; Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002 Dec 15;20(24):4665-72. [http://jco.ascopubs.org/content/20/24/4665.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/12488411 PubMed] | # Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S; Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002 Dec 15;20(24):4665-72. [http://jco.ascopubs.org/content/20/24/4665.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/12488411 PubMed] | ||
| − | + | ==Cisplatin 80 mg/m2 & Etoposide 80 mg/m2== | |
| − | + | ===Regimen=== | |
*[[Cisplatin (Platinol)]] 80 mg/m2 IV day 1 | *[[Cisplatin (Platinol)]] 80 mg/m2 IV day 1 | ||
*[[Etoposide (Vepesid)]] 80 mg/m2 IV days 1-3 | *[[Etoposide (Vepesid)]] 80 mg/m2 IV days 1-3 | ||
| Line 74: | Line 74: | ||
'''21-day cycles x 4-6 cycles''' | '''21-day cycles x 4-6 cycles''' | ||
| − | + | ===References=== | |
# Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994 Oct;12(10):2022-34. [http://jco.ascopubs.org/content/12/10/2022.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/7931470 PubMed] | # Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994 Oct;12(10):2022-34. [http://jco.ascopubs.org/content/12/10/2022.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/7931470 PubMed] | ||
| − | + | ==Cisplatin 25 mg/m2 & Etoposide 100 mg/m2== | |
| − | + | ===Regimen=== | |
*[[Cisplatin (Platinol)]] 25 mg/m2 IV days 1-3 | *[[Cisplatin (Platinol)]] 25 mg/m2 IV days 1-3 | ||
*[[Etoposide (Vepesid)]] 100 mg/m2 IV days 1-3 | *[[Etoposide (Vepesid)]] 100 mg/m2 IV days 1-3 | ||
| Line 84: | Line 84: | ||
'''21-day cycles x 4-6 cycles''' | '''21-day cycles x 4-6 cycles''' | ||
| − | + | ===References=== | |
# Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 1985 Nov;3(11):1471-7. [http://jco.ascopubs.org/content/3/11/1471.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/2997406 PubMed] | # Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 1985 Nov;3(11):1471-7. [http://jco.ascopubs.org/content/3/11/1471.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/2997406 PubMed] | ||
| − | + | ==Cisplatin 30 mg/m2 & Irinotecan 65 mg/m2== | |
| − | + | ===Regimen=== | |
*[[Cisplatin (Platinol)]] 30 mg/m2 IV days 1 & 8 | *[[Cisplatin (Platinol)]] 30 mg/m2 IV days 1 & 8 | ||
*[[Irinotecan (Camptosar)]] 65 mg/m2 IV days 1 & 8 | *[[Irinotecan (Camptosar)]] 65 mg/m2 IV days 1 & 8 | ||
| Line 94: | Line 94: | ||
'''21-day cycles x 4-6 cycles''' | '''21-day cycles x 4-6 cycles''' | ||
| − | + | ===References=== | |
# Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006 May 1;24(13):2038-43. [http://jco.ascopubs.org/content/24/13/2038.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/16648503 PubMed] | # Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006 May 1;24(13):2038-43. [http://jco.ascopubs.org/content/24/13/2038.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/16648503 PubMed] | ||
| − | + | ==Cisplatin 60 mg/m2 & Irinotecan 60 mg/m2== | |
| − | + | ===Regimen=== | |
*[[Cisplatin (Platinol)]] 60 mg/m2 IV day 1 | *[[Cisplatin (Platinol)]] 60 mg/m2 IV day 1 | ||
*[[Irinotecan (Camptosar)]] 60 mg/m2 IV days 1, 8, 15 | *[[Irinotecan (Camptosar)]] 60 mg/m2 IV days 1, 8, 15 | ||
| Line 104: | Line 104: | ||
'''28-day cycles x 4-6 cycles''' | '''28-day cycles x 4-6 cycles''' | ||
| − | + | ===References=== | |
# Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):85-91. [http://www.nejm.org/doi/full/10.1056/NEJMoa003034 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/11784874 PubMed] | # Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):85-91. [http://www.nejm.org/doi/full/10.1056/NEJMoa003034 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/11784874 PubMed] | ||
| − | + | ==Carboplatin & Etoposide== | |
| − | + | ===Regimen=== | |
*[[Carboplatin (Paraplatin)]] AUC 5-6 IV day 1 | *[[Carboplatin (Paraplatin)]] AUC 5-6 IV day 1 | ||
*[[Etoposide (Vepesid)]] 100 mg/m2 IV days 1-3 | *[[Etoposide (Vepesid)]] 100 mg/m2 IV days 1-3 | ||
| Line 114: | Line 114: | ||
'''21-day cycles x 4-6 cycles''' | '''21-day cycles x 4-6 cycles''' | ||
| − | + | ===References=== | |
# Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol. 1999 Nov;17(11):3540-5. [http://jco.ascopubs.org/content/17/11/3540.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/10550152 PubMed] | # Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol. 1999 Nov;17(11):3540-5. [http://jco.ascopubs.org/content/17/11/3540.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/10550152 PubMed] | ||
| − | + | ==Carboplatin & Irinotecan== | |
| − | + | ===Regimen=== | |
*[[Carboplatin (Paraplatin)]] AUC 5 IV day 1 | *[[Carboplatin (Paraplatin)]] AUC 5 IV day 1 | ||
*[[Irinotecan (Camptosar)]] 50 mg/m2 IV days 1, 8, 15 | *[[Irinotecan (Camptosar)]] 50 mg/m2 IV days 1, 8, 15 | ||
| Line 124: | Line 124: | ||
'''28-day cycles x 4-6 cycles''' | '''28-day cycles x 4-6 cycles''' | ||
| − | + | ===References=== | |
# Schmittel A, Fischer von Weikersthal L, Sebastian M, Martus P, Schulze K, Hortig P, Reeb M, Thiel E, Keilholz U. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol. 2006 Apr;17(4):663-7. Epub 2006 Jan 19. [http://annonc.oxfordjournals.org/content/17/4/663.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/16423848 PubMed] | # Schmittel A, Fischer von Weikersthal L, Sebastian M, Martus P, Schulze K, Hortig P, Reeb M, Thiel E, Keilholz U. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol. 2006 Apr;17(4):663-7. Epub 2006 Jan 19. [http://annonc.oxfordjournals.org/content/17/4/663.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/16423848 PubMed] | ||
# Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C, Hortig P, Fischer JR, Link H, Binder D, Fischer B, Caca K, Eberhardt WE, Keilholz U; Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol. 2011 Aug;22(8):1798-804. Epub 2011 Jan 25. [http://annonc.oxfordjournals.org/content/22/8/1798.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/21266516 PubMed] | # Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C, Hortig P, Fischer JR, Link H, Binder D, Fischer B, Caca K, Eberhardt WE, Keilholz U; Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol. 2011 Aug;22(8):1798-804. Epub 2011 Jan 25. [http://annonc.oxfordjournals.org/content/22/8/1798.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/21266516 PubMed] | ||
Revision as of 04:07, 21 April 2012
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Limited stage
Cisplatin 60 mg/m2, Etoposide 120 mg/m2, RT
Regimen
- Cisplatin (Platinol) 60 mg/m2 IV day 1
- Etoposide (Vepesid) 120 mg/m2 IV days 1-3
- Concurrent radiation therapy of 1.8 Gy fractions given once a day for a total of 54-61 Gy or 1.5 Gy fractions given twice a day for a total of 45 Gy
21-day cycles x 4-6 cycles
References
- Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999 Jan 28;340(4):265-71. link to original article PubMed
Cisplatin 80 mg/m2, Etoposide 100 mg/m2, RT
Regimen
- Cisplatin (Platinol) 80 mg/m2 IV day 1
- Etoposide (Vepesid) 100 mg/m2 IV days 1-3
- Concurrent radiation therapy of 1.5 Gy fractions given twice a day for a total of 45 Gy
28-day cycles x 4-6 cycles
References
- Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, Nishiwaki Y, Watanabe K, Noda K, Tamura T, Fukuda H, Saijo N. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002 Jul 15;20(14):3054-60. link to original article PubMed
- Saito H, Takada Y, Ichinose Y, Eguchi K, Kudoh S, Matsui K, Nakagawa K, Takada M, Negoro S, Tamura K, Ando M, Tada T, Fukuoka M; West Japan Thoracic Oncology Group 9902. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol. 2006 Nov 20;24(33):5247-52. link to original article PubMed
Cisplatin, Etoposide, RT -> Cisplatin & Irinotecan
Regimen
- Cisplatin (Platinol) 80 mg/m2 IV day 1
- Etoposide (Vepesid) 100 mg/m2 IV days 1-3
- Concurrent radiation therapy of 1.5 Gy fractions given twice a day for a total of 45 Gy
28-day initial cycle, THEN
- Cisplatin (Platinol) 60 mg/m2 IV day 1
- Irinotecan (Camptosar) 60 mg/m2 IV days 1, 8, 15
28-day cycles x 3 cycles
References
- Saito H, Takada Y, Ichinose Y, Eguchi K, Kudoh S, Matsui K, Nakagawa K, Takada M, Negoro S, Tamura K, Ando M, Tada T, Fukuoka M; West Japan Thoracic Oncology Group 9902. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol. 2006 Nov 20;24(33):5247-52. link to original article contains protocol PubMed
Carboplatin, Etoposide, RT
Regimen
- Carboplatin (Paraplatin) AUC 5-6 IV over 1 hour on day 1 (administered first)
- Etoposide (Vepesid) 100 mg/m2 IV over 2 hours on days 1-3 (administered second)
- Concurrent radiation therapy of 1.5 Gy fractions given twice a day for a total of 45 Gy (given during either the first or fourth cycle of chemotherapy)
21-day cycles x up to 6 cycles
References
- Skarlos DV, Samantas E, Briassoulis E, Panoussaki E, Pavlidis N, Kalofonos HP, Kardamakis D, Tsiakopoulos E, Kosmidis P, Tsavdaridis D, Tzitzikas J, Tsekeris P, Kouvatseas G, Zamboglou N, Fountzilas G. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2001 Sep;12(9):1231-8. link to original article contains protocol PubMed
Extensive stage
Cisplatin 75 mg/m2 & Etoposide 100 mg/m2
Regimen
- Cisplatin (Platinol) 75 mg/m2 IV day 1
- Etoposide (Vepesid) 100 mg/m2 IV days 1-3
21-day cycles x 4-6 cycles
References
- Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S; Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002 Dec 15;20(24):4665-72. link to original article PubMed
Cisplatin 80 mg/m2 & Etoposide 80 mg/m2
Regimen
- Cisplatin (Platinol) 80 mg/m2 IV day 1
- Etoposide (Vepesid) 80 mg/m2 IV days 1-3
21-day cycles x 4-6 cycles
References
- Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994 Oct;12(10):2022-34. link to original article PubMed
Cisplatin 25 mg/m2 & Etoposide 100 mg/m2
Regimen
- Cisplatin (Platinol) 25 mg/m2 IV days 1-3
- Etoposide (Vepesid) 100 mg/m2 IV days 1-3
21-day cycles x 4-6 cycles
References
- Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 1985 Nov;3(11):1471-7. link to original article PubMed
Cisplatin 30 mg/m2 & Irinotecan 65 mg/m2
Regimen
- Cisplatin (Platinol) 30 mg/m2 IV days 1 & 8
- Irinotecan (Camptosar) 65 mg/m2 IV days 1 & 8
21-day cycles x 4-6 cycles
References
- Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006 May 1;24(13):2038-43. link to original article PubMed
Cisplatin 60 mg/m2 & Irinotecan 60 mg/m2
Regimen
- Cisplatin (Platinol) 60 mg/m2 IV day 1
- Irinotecan (Camptosar) 60 mg/m2 IV days 1, 8, 15
28-day cycles x 4-6 cycles
References
- Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):85-91. link to original article PubMed
Carboplatin & Etoposide
Regimen
- Carboplatin (Paraplatin) AUC 5-6 IV day 1
- Etoposide (Vepesid) 100 mg/m2 IV days 1-3
21-day cycles x 4-6 cycles
References
- Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol. 1999 Nov;17(11):3540-5. link to original article PubMed
Carboplatin & Irinotecan
Regimen
- Carboplatin (Paraplatin) AUC 5 IV day 1
- Irinotecan (Camptosar) 50 mg/m2 IV days 1, 8, 15
28-day cycles x 4-6 cycles
References
- Schmittel A, Fischer von Weikersthal L, Sebastian M, Martus P, Schulze K, Hortig P, Reeb M, Thiel E, Keilholz U. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol. 2006 Apr;17(4):663-7. Epub 2006 Jan 19. link to original article PubMed
- Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C, Hortig P, Fischer JR, Link H, Binder D, Fischer B, Caca K, Eberhardt WE, Keilholz U; Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol. 2011 Aug;22(8):1798-804. Epub 2011 Jan 25. link to original article PubMed